The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
34
intravenous infusion
Research Site
Glendale, California, United States
Research Site
Hartford, Connecticut, United States
Research Site
New Haven, Connecticut, United States
Research Site
Wichita, Kansas, United States
Research Site
The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score.
Time frame: Change from Baseline
The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events.
Time frame: each visit; change from baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rockville, Maryland, United States